S100A8 and serum lipopolysaccharide activity: We demonstrate that high S100A8/A9 levels are associated with acute LV dysfunction in patients with severe sepsis, and that pharmacologic S100A8/A9 blockade with the small-molecule inhibitor ABR-238901 can mitigate myocardial dysfunction in endotoxemia.